Neuroendocrine responses to serotonergic agonists as indices of the functional status of central serotonin neurotransmission in humans: A preliminary comparative analysis of neuroendocrine endpoints versus other endpoint measures

Behavioural Brain Research

Volumn 73, Issue 1-2, 1995, Pages 209-214

  Murphy, Dennis L ^a   Aulakh, Charanjit ^a   Mazzola Pomietto, Pascale ^a   Briggs, Nathaniel C ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Anxiety; Cortisol; m Chlorophenylpiperazine; Prolactin; Serotonin; Serotonin receptor; Temperature

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PROLACTIN; SEROTONIN RECEPTOR;

ANXIETY; BEHAVIOR; CONFERENCE PAPER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THERMOREGULATION;

BEHAVIOR; HUMANS; NEUROSECRETORY SYSTEMS; SEROTONIN; SEROTONIN AGONISTS; SYNAPTIC TRANSMISSION;

EID: 0030028695     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-4328(96)00098-8     Document Type: Article

References (51)

1. Neuroendocrine and behavioral responses to intravenous m-Chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects
2. Long-term imipramine treatment enhances the locomotor and food intake suppressant effects of m-chlorophenylpiperazine in rats
3. Long-term imipramine treatment potentiates m-chlorophenylpiperazine-induced changes in prolactin but not corticosterone or growth hormone levels in rats
4. Differential effect of short- and long-term lithium treatment on m-CPP-induced neuroendocrine changes in rats
5. Effects of various serotonin receptor subtype selective antagonists alone and on m-CPP-induced neuroendocrine changes in rats
6. Clorgyline treatment differentially affects m-chlorophenylpiperazine-induced neuroendocrine changes
7. Long-term lithium treatment in rats attenuates m-chlorophenylpiperazine-induced decreases in food intake but not locomotor activity
8. 2 receptor agonist-induced oxytocin, prolactin, and corticosterone responses
9. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats
10. Eating disorders, anxiety, and 5-HT
11. Neuroendocrine responses to m-chlorophenylpiperazine and l-tryptophan in bulimina
12. Effect of seletive serotonin agonists on basal, corticotrophin-releasing hormone- and vasopressin-induced ACTH release in vitro from rat pituitary cells
13. 3H]5-HT from human perfused platelets
14. Serotonin function in anxiety. II. Effects of serotonin agonist m-CPP in panic disorder patients and healthy subjects
15. Long-term clorgyline treatment antagonizes the eating and motor function responses to m-chlorophenylpiperazine
16. 1C) receptors
17. Neuroendocrine effects of azapirones
18. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain
19. Effects of serotonergic agonists on neuroendocrine responses of rhesus monkeys and patients with depression and anxiety disorders
20. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder
21. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
22. Behavioral responses to intravenous meta-chlorophenylpiperazine in patients with seasonal affective disorder and control subjects before and after phototherapy
23. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder
24. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects
25. m-Chlorophenylpiperazine as a probe of serotonin function
26. Behavioral indications for serotonin receptor hypersensitivity in panic disorder
27. 1C receptor antagonists
28. Evidence for a decline with age in behavioral responsivity to the serotonin agonist, m-chlorophenylpiperazine, in healthy human subjects
29. Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study
30. 1A receptor sensitivity in depression and anxiety disorders: molecular mechanisms of neuroadaptation
31. 1C receptors
32. The neuroendocrine approach to psychiatric disorders: a critical appraisal
33. Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes and subsystems
34. Peripheral indices of central serotonin function in humans
35. Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans
36. Hormonal responses to serotonergic drugs as a means to evaluate brain serotonergic function in humans
37. Monoamine function in anxiety and depression Information from neuroendocrine challenge tests
38. Effects of clozapine and fluphenazine treatment on responses to m-chlorophenylpiperazine infusions in schizophrenia
39. A comparison of the behavioral effects of oral versus intravenous m-CPP administration in OCD patients and the effect of metergoline prior to IV m-CPP
40. Neuroendocrine challenge tests: assessment of 5-HT function in anxiety and depression
41. 1A (antagonistic) activity
42. 3 receptors
43. 1B receptor ligands exists?
44. 1C receptor ‘knockout’ mice
45. The 5-HT transporter is an additional site of action for the 5-HT agonists RU 24969 and TFMPP
46. Differential effect of clomipramine treatment on m-chlorophenylpiperazine-induced increases in plasma prolactin and corticosterone in rats
47. Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments
48. Neuroendocrine probes of serotonergic function: a critical review
49. Serotonergic responsivity in obsessive-compulsive disorder: Effects of chronic clomipramine treatment
50. Serotonergic responsivity in obsessive-compulsive disorder: Comparison of patients and healthy controls